Scotland backs Pfizer’s Ibrance for breast cancerPfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced Share XScotland backs Pfizer’s Ibrance for breast cancerhttps://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/
Federal court puts kibosh on Trump plan for drug prices in TV adsA federal judge has blown a hole in an attempt by the Trump administration to force drugmakers to Share XFederal court puts kibosh on Trump plan for drug prices in TV adshttps://pharmaphorum.com/news/federal-court-puts-kibosh-on-trump-plan-for-drug-prices-in-tv-ads/
AMAG bags FDA okay for second ‘female Viagra’ drugAMAG Pharma has won US approval for a new drug to treat decreased libido in premenopausal that will Share XAMAG bags FDA okay for second ‘female Viagra’ drughttps://pharmaphorum.com/news/amag-bags-fda-okay-for-second-female-viagra-drug/
NICE backs Alimera’s three-year uveitis implantAn implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that Share XNICE backs Alimera’s three-year uveitis implanthttps://pharmaphorum.com/news/nice-backs-alimeras-three-year-uveitis-implant/
Vaccines mistrust a “global crisis” says Wellcome reportA wide-ranging survey involving 140,000 people in 140 countries has revealed a worryingly high level of concern about Share XVaccines mistrust a “global crisis” says Wellcome reporthttps://pharmaphorum.com/news/vaccines-mistrust-a-global-crisis-says-wellcome-report/
Merck claims a brace of head and neck cancer approvalsMerck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals Share XMerck claims a brace of head and neck cancer approvalshttps://pharmaphorum.com/news/merck-claims-a-brace-of-head-and-neck-cancer-approvals/
ICER posts damning report on Sarepta’s Duchenne drug Exondys 51Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of Share XICER posts damning report on Sarepta’s Duchenne drug Exondys 51https://pharmaphorum.com/news/icer-posts-damning-report-on-sareptas-duchenne-drug-exondys-51/
Roche’s entrectinib hits the mark in paediatric cancersRoche’s entrectinib for gene fusion-positive cancers has shown promising results in a range of paediatric cancers in an Share XRoche’s entrectinib hits the mark in paediatric cancershttps://pharmaphorum.com/news/roches-entrectinib-hits-the-mark-in-paediatric-cancers/
Health secretary urged to investigate epilepsy medicine shortageHealth Secretary Matt Hancock has been urged to immediately review the epilepsy medicine supply chain, after ongoing problems Share XHealth secretary urged to investigate epilepsy medicine shortagehttps://pharmaphorum.com/news/health-secretary-urged-to-investigate-epilepsy-medicine-shortage/
